Requirements

The T1D Innovation Grant Program is a global initiative designed to foster groundbreaking research in type 1 diabetes (T1D) worldwide. We invite applications from dedicated researchers in the countries listed below who are committed to advancing the understanding of T1D and improving health outcomes in affected individuals. Submissions from applicants based in countries not explicitly listed below cannot be considered at this time. We encourage all prospective applicants to carefully review the eligibility criteria and geographical scope to determine their suitability for this unique funding opportunity.

What types of research projects are eligible for this funding?

We seek innovative research projects that explore translational immunology in T1D. Areas of interest within the scope of this initiative include:

• Novel pathways of autoimmunity in T1D
• New approaches to early detection of individuals at risk of T1D
• Biomarker strategies, especially for prediction of T1D disease progression, and for stratification for clinical response to immunotherapy
• Applications of artificial intelligence and/or machine learning in any of the above research topics

Which projects are not eligible for funding?

The following types of research projects are not eligible for funding:

• Research connected to any Sanofi product
• Studies for which extensive data is already published
• Comparative drug trials, randomized clinical trials, placebo-controlled trials, follow-ups
to previous clinical studies that include treatment, or real-world evidence studies
that include treatment. Nor studies requiring a drug supply
• Studies for which the risk/benefit of any intervention (e.g., monitoring method)
is considered uncertain, based on the scientific rationale, mechanism of action,
and potential safety concerns
• Research projects that are already included in Investigator-Sponsored Studies by Sanofi and/or listed on www.clinicaltrials.gov